Therapy with Erespal in patients with chronic obstructive pulmonary disease

Comparative efficacy of long-tem treatment with Erespal (fenspirid, Servier) and Atrovent as the basic therapy of patients with COPD exacerbation was studied. The patients with clinical and laboratory signs of COPD exacerbation were involved in the study. Patients treated by oral or inhaled glucocorticosteroids, with severe concomitant diseases and with acute exacerbations of chronic co-existing diseases were excluded. The patients were randomized into 2 groups: the 1-st group patients (n = 35) were treated with Erespal 160 mg daily during 3 months, the 2-nd group patients (n = 32) were treated with Atrovent 40 meg 3 to 4 times daily. The efficacy was evaluated by visual scoring of cough and dyspnoea severity, sputum volume, elastase-like and tripsin-like serum and sputum activities, TNF-a serum and sputum levels, lung function parameters, cell number in induced sputum and bronchial mucus brushing. A reliable improvement (p < 0.05) in clinical symptoms was observed in both the groups at the end of the treatment, but the dyspnoea decreased reliably (p < 0.05) only in the patients treated with Erespal. The lung function parameters were considerably improved (p < 0.05) in both the groups. The elastase-like and tripsin-like serum and sputum activities and the TNF-a serum and sputum levels were significantly decreased (p < 0.05) only in the patients treated with Erespal. The neutrophil number was reliably decreased (p < 0 .0001 ) and macrophages number was reliably increased (p<0 .0 0 0 1 ) in the induced sputum, atrophic and proliferating bronchial epithelial cell counts were reliably decreased (p < 0.05) in the 1-st group patients compared with the 2-nd group. Thus, Erespal is effective antiinflammatory drug for treatment of COPD patients. Persisting bronchial inflammation at clinically stable period (after 3-month therapy) is a reason to include Erespal in the basic therapy of COPD.

1. Chuchalin A.G. Pul'monologiya v Rossii i puti ee razvitiya. Rus. med. zhurn. 2000; 8 (7): 1-5.

2. Shmelev E.I. Khronicheskaya obstruktivnaya bolezn' legkikh. Pul'monologiya. Izbran, vopr. 1000; 2: 1-9.

3. Aisanov Z.R., Kokosov A.N., Ovcharenko S.I. i dr. Khroniches­ kie obstruktivnye bolezni legkikh. Federal'naya programma. Rus. med. zhurn. 2001; 9 (1): 9-32.

4. Chuchalin A.G. Khronicheskie obstruktivnye bolezni legkikh. M.: Binom; SPb.: Nevskii dialekt; 1998.

5. Ovcharenko S.I. Protivovospalitel'naya terapiya khronicheskogo bronkhita. Rus. med. zhurn. 2001; 9 (5): 201-204.

6. Anto J.M., Vermier P., Sunyer J. Chronic obstructive pulmonary disease. Eur. Respir. Mon. 2000; 15: 1-22.

7. Kokosov A.N. Bolezni organov dykhaniya. Klinika i lechenie. SPb; 1999.

8. Lin B.Q., Peto R., Chen Z.M . et al. Emergins tobacco hazards in China. I. Retrospective mortality study of one million deathes. Br. Med. J. 1998; 317: 1411-1422.

9. Murrey C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Braden of Disease Study. Lancet 1997; 349: 1498-1504.

10. Sinopal'nikov A.I., Fesenko O.V., Maev E.Z. Antibiotiki i khronicheskii bronkhit. Infektsii i antimikrob, khimioter. 1999; 1 (1): 4-7.

11. Holmes W.F. Traditionale treatment in the community. Eur. Respir. Rev. 2000; 10 (71): 156-160.

12. Global initiative for chronic obstructive lung disease. Geneve: W HO; 2001.

13. White M.V., Kaliner M.A. Histamine in allergic disease. In: Simons F.E.R., ed. Histamine and H 1-receptor antagonists in allergic disease. New York: Marcel Dekker; 1996. 61-91.

14. Eurarde Y., Kato G., Bodinier M.C. Chapelain V. Fenspiride and inflammation in experimental pharmacology. Eur. Respir. Rev. 1991; 1 (rev.2): 93-100.

15. Pipy B., Evrard Y. Inflammation experimentale et effects du fenspiride sur les cytokine, les metabolites de l'acide arachidonique et la migratin cellulaire. Lettre Pharmacol. 1992; 6 (suppl.7): 13-19.

16. Broillet A., White R., Ventrone R., Glessinger N. Efficasity du fenspiride dans la brondute chronique induite pur le S02 chez le rat et dans la rhinite allergique du cobaye. Rhinology 1988; suppl.4: 77-86.

17. Lima M., Hatrnil M., M artins M. et al. Médiateurs de l'inflammation et antagonisme par le fenspiride de la pleuresie expéri­ mentale chez le rat. Rhinology 1988; suppl.4: 87-95.

18. Quartulli F., Pinelli E. et al. Le fenspiride inhibe les réponses induites par l'histamine dans une lignee cellulaire epitheliale pul­ monaire. Eur. J. Pharmacol. 1998; 34: 297-304.

19. Sozzani P., Cambon C., Frisach M.F. et al. Fenspiride inhibits phosphatidyl inositol hydrolysis in mouse inflammatory macrophages. Eur. Respir. J. 1993; 6 (suppl. 17): 3055-3077.

20. Bezlepko A.V. Opyt dlitel'nogo primeneniya fenspirida (erespala) pri lechenii bol'nykh khronicheskim obstruktivnym bronkhitom (soobshchenie vtoroe). Pul'monologiya 2002; 3: 76-82.

21. Akount G., Arnaud F., Blarichot F. Effects du (Pneumorel 80) sur la fonction respiratorie et la patients présentant, une bronchopathie chronique obstructive stable. Eur. Respir. Rev. 1991; 1 (suppl.2): 51-65.

22. Leophonte P., Thuch K.S., Voigt J.J. et al. Le fenspiride (pneumorel) danus le traitment des bronchopneumopathies chroniques obstructives. Vie Med. 1986; 67: 1047-1057.

23. Lirsac B., Benezet O., Dansin E. et al. Evaluation and symptomatic treatment of surinfections exacerbations of COPD: preliminary study of antibiotic treatment combined with fenspiride (pnuemoferol 80 mg) versus placebo. Rev. Pneumol. Clin. 2000; 56 (1): 17-24.

24. Ogloblina O.G., Platonova Jl.V., Paskhina T.S. Izmerenie aktivnosti tripsino- i elatazopodobnykh proteinaz polimorfnoyadernykh leikotsitov i urovnya ikh kislotostabil'nykh ingibitorov v bronkhial'nom sekrete cheloveka: Metod, rekomendatsii. M.: MGU; 1984.